ARTICLE | Product Development
CRISPR shines in another application with Caribou’s first CAR T data
Caribou’s first clinical data suggest PD-1 knockout may drive up allogeneic CAR T efficacy, durability
May 12, 2022 2:14 PM UTC
The first look at clinical data from Caribou’s CRISPR-based gene editing platform suggests knocking out PD-1 may be a key piece of the solution to allogeneic CAR T cell problems.
It also makes CAR T cells the latest modality to benefit from, and build confidence in, the transformational potential of the gene editing technology. ...